Skip to main content
Category

Treatments

ResearchTreatments

ODAC Recommends New Trial Data of Sintilimab in US Population of Frontline NSCLC

*February 2022* The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application (BLA) for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer (NSCLC). ODAC concluded that supporting data from the phase…
ResearchTreatments

INSIGHT 2: a phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance

*December 2021* Osimertinib is used to treat a type of lung cancer that has specific changes (mutations) in a gene called EGFR. Although tumors will usually shrink (respond) during treatment with osimertinib, they can stop responding, or become resistant, to osimertinib. A common cause of resistance is ‘MET amplification’, which…
ResearchTreatments

Slide Decks from the 2022 Targeted Therapies Meeting

*February 2022* Open Questions Around First-Line Treatment for EGFR Mutant Lung Cancers, Dr Helena Yu, presenter Acquired Resistance to EGFR TKIs, Dr. Katerina Politi, presenter Histological transformation and off target mechanisms are frequently identified on disease progression for patients with EGFRmutant lung cancer treated with first-line osimertinib, Dr. Noura Choudhury,…
laurabbook@gmail.com
March 18, 2022
ResearchTreatments

Detection of acquired TERT amplification in addition to predisposing p53 and Rb pathways alterations in EGFR-mutant lung adenocarcinomas transformed into small-cell lung cancers

*January 2022* Highlights: p53 and Rb alterations are confirmed as predisposing to SCLC transformation in EGFR- LUAD. Paired EGFR-LUAD/SCLC samples showed diverse clonal evolution patterns. TERT amplification is an acquired event during EGFR-LUAD to SCLC transformation. Introduction Among the different mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs)…
laurabbook@gmail.com
March 18, 2022
ResearchTreatments

Research Articles on HER2 and Exon 20 Mutations in NSCLC

*March 2022* Human Epidermal Growth Factor Receptor 2–Mutant Non–Small-Cell Lung Cancer: Continued Progress But Challenges Remain Combination of Trastuzumab, Pertuzumab, and Docetaxel in Patients With Advanced Non–Small-Cell Lung Cancer Harboring HER2 Mutations: Results From the IFCT-1703 R2D2 Trial FDA Grants Breakthrough Therapy Designation to DZD9008 for EGFR Exon20Ins-Positive NSCLC
laurabbook@gmail.com
March 18, 2022
ResearchTreatments

Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence

*January 2022* Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. We conducted a systematic review to investigate the available data on this patients’ subgroup. Overall, we found a high heterogeneity in the incidence of compound mutations (4–26% of…
laurabbook@gmail.com
March 18, 2022
ResearchTreatments

Single cell DNA-seq depicts clonal evolution of multiple driver alterations in osimertinib resistant patients

*January 2022* Highlights Clonal architecture of molecular alterations at the cellular level depicts cancer cell adaptation during targeted therapy. Single cell sequencing from patient biopsies revealed the co-existence of two driver alterations within single cancer cells. Pharmacological evaluation in patient derived models asserts the need of simultaneous inhibition of each driver. Read…
laurabbook@gmail.com
March 18, 2022